Key result
Pravastatin shows borderline improvement in early morphologic recovery of non-hemorrhagic vertebral artery dissection versus control.
Why the study?
Information regarding the pleiotropic effects of statins on cerebrovascular diseases, including non-hemorrhagic vertebral artery dissection, was limited.
Does pravastatin improve radiologic changes on vessel wall MRI in patients with non-hemorrhagic vertebral artery dissection?
RCT (n=23)
Single-blind
Random Allocation Software 1.0
Yes
Does pravastatin improve radiologic changes on vessel wall MRI in patients with non-hemorrhagic vertebral artery dissection?
Answers are grounded in this paper and cite their sources.
Pravastatin did not significantly improve morphological recovery of non-hemorrhagic vertebral artery dissection after adjusting for baseline age differences, though it was safe and lowered inflammatory markers.
There is limited information about the pleiotropic effects of statin on cerebrovascular diseases. The authors aimed to investigate the effect of pravastatin on non-hemorrhagic vertebral artery dissection (VAD) in a clinical setting. An exploratory randomized and controlled study was designed for the non-hemorrhage VAD (CRIS, KCT00035970). Primary outcomes were 1- and 6-month radiologic changes on vessel wall magnetic resonance imaging (VW-MRI), with secondary outcomes related to the clinical and laboratory parameters, and safety outcomes of the pravastatin use. Finally, 23 patients were enrolled, consisting of 12 in the pravastatin group and 11 in the control with similar baseline characteristics except the age (55.0 versus 45.5 years, P = .01). Morphologic changes in the early period (0–1 month) were more improved or resolved in the pravastatin group with a borderline significance (crude odds ratio: 7.500 [95% confidence interval: 0.921-64.047], P = .06). However, age-adjusted analysis showed no difference in morphologic changes between the groups (adjusted odds ratio: 0.853 [95% confidence interval: 0.033-22.020], P = .92). The serum level of high-sensitivity C-reactive protein (hs-CRP) in the pravastatin group showed a descending tendency in the early period (Z-score: -1.843, P = .07), whereas it significantly increased in the control (Z-score: -2.371, P = .02). There were no safety issues at all. Pravastatin had a borderline significant effect on the recovery of non-hemorrhage VAD with no additional adverse effects. A further study with a larger scale is expected to make more concrete evidences about the pleiotropic effects of statin on the non-hemorrhagic VAD. The present study registered in a clinical research information service approved by World Health Organization (CRIS, KCT00035970, Registered on 7 March 2019; available at: https://cris.nih.go.kr/cris/search/detailSearch.do?seq=25234%26status=5%26seq_group=12949%26search_page=M ).
No takes yet. Share an insight, caveat, or question.
Han et al. (2025) conducted an RCT in Non-hemorrhagic vertebral artery dissection (n=23). Pravastatin vs. Aspirin 100 mg and antacid was evaluated on Improved or resolved morphologic changes on vessel wall MRI at 1 month (OR 7.500, 95% CI 0.921-64.047, p=0.06). Pravastatin showed a borderline significant improvement in early morphologic recovery of non-hemorrhagic vertebral artery dissection compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: